354 related articles for article (PubMed ID: 35067907)
1. An update on mode of action of metformin in modulation of meta-inflammation and inflammaging.
Khodadadi M; Jafari-Gharabaghlou D; Zarghami N
Pharmacol Rep; 2022 Apr; 74(2):310-322. PubMed ID: 35067907
[TBL] [Abstract][Full Text] [Related]
2. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus.
Foretz M; Guigas B; Viollet B
Nat Rev Endocrinol; 2019 Oct; 15(10):569-589. PubMed ID: 31439934
[TBL] [Abstract][Full Text] [Related]
3. Metformin as an Anticancer Agent.
Vancura A; Bu P; Bhagwat M; Zeng J; Vancurova I
Trends Pharmacol Sci; 2018 Oct; 39(10):867-878. PubMed ID: 30150001
[TBL] [Abstract][Full Text] [Related]
4. New Insight into the Effects of Metformin on Diabetic Retinopathy, Aging and Cancer: Nonapoptotic Cell Death, Immunosuppression, and Effects beyond the AMPK Pathway.
Hsu SK; Cheng KC; Mgbeahuruike MO; Lin YH; Wu CY; Wang HD; Yen CH; Chiu CC; Sheu SJ
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502359
[TBL] [Abstract][Full Text] [Related]
5. The mechanisms of action of metformin.
Rena G; Hardie DG; Pearson ER
Diabetologia; 2017 Sep; 60(9):1577-1585. PubMed ID: 28776086
[TBL] [Abstract][Full Text] [Related]
6. Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect.
Saisho Y
Endocr Metab Immune Disord Drug Targets; 2015; 15(3):196-205. PubMed ID: 25772174
[TBL] [Abstract][Full Text] [Related]
7. Mechanism and application of metformin in kidney diseases: An update.
Song A; Zhang C; Meng X
Biomed Pharmacother; 2021 Jun; 138():111454. PubMed ID: 33714781
[TBL] [Abstract][Full Text] [Related]
8. Metformin--mode of action and clinical implications for diabetes and cancer.
Pernicova I; Korbonits M
Nat Rev Endocrinol; 2014 Mar; 10(3):143-56. PubMed ID: 24393785
[TBL] [Abstract][Full Text] [Related]
9. Metformin-induced inhibition of the mitochondrial respiratory chain increases FGF21 expression via ATF4 activation.
Kim KH; Jeong YT; Kim SH; Jung HS; Park KS; Lee HY; Lee MS
Biochem Biophys Res Commun; 2013 Oct; 440(1):76-81. PubMed ID: 24041694
[TBL] [Abstract][Full Text] [Related]
10. Metformin as an anti-inflammatory agent: a short review.
Kristófi R; Eriksson JW
J Endocrinol; 2021 Sep; 251(2):R11-R22. PubMed ID: 34463292
[TBL] [Abstract][Full Text] [Related]
11. Metformin action on AMP-activated protein kinase: a translational research approach to understanding a potential new therapeutic target.
Boyle JG; Salt IP; McKay GA
Diabet Med; 2010 Oct; 27(10):1097-106. PubMed ID: 20854376
[TBL] [Abstract][Full Text] [Related]
12. The development and benefits of metformin in various diseases.
Dong Y; Qi Y; Jiang H; Mi T; Zhang Y; Peng C; Li W; Zhang Y; Zhou Y; Zang Y; Li J
Front Med; 2023 Jun; 17(3):388-431. PubMed ID: 37402952
[TBL] [Abstract][Full Text] [Related]
13. A reappraisal on metformin.
Adak T; Samadi A; Ünal AZ; Sabuncuoğlu S
Regul Toxicol Pharmacol; 2018 Feb; 92():324-332. PubMed ID: 29291990
[TBL] [Abstract][Full Text] [Related]
14. Knocking on GDF15's door for the treatment of type 2 diabetes mellitus.
Aguilar-Recarte D; Barroso E; Palomer X; Wahli W; Vázquez-Carrera M
Trends Endocrinol Metab; 2022 Nov; 33(11):741-754. PubMed ID: 36151002
[TBL] [Abstract][Full Text] [Related]
15. Metformin: from mechanisms of action to therapies.
Foretz M; Guigas B; Bertrand L; Pollak M; Viollet B
Cell Metab; 2014 Dec; 20(6):953-66. PubMed ID: 25456737
[TBL] [Abstract][Full Text] [Related]
16. Convergence of IPMK and LKB1-AMPK signaling pathways on metformin action.
Bang S; Chen Y; Ahima RS; Kim SF
Mol Endocrinol; 2014 Jul; 28(7):1186-93. PubMed ID: 24877601
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effects of metformin on glomerular podocytes in diabetes.
Rogacka D; Piwkowska A
Biochem Pharmacol; 2021 Oct; 192():114687. PubMed ID: 34274355
[TBL] [Abstract][Full Text] [Related]
18. Molecular action of metformin in hepatocytes: an updated insight.
Sliwinska A; Drzewoski J
Curr Diabetes Rev; 2015; 11(3):175-81. PubMed ID: 25808533
[TBL] [Abstract][Full Text] [Related]
19. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state.
Foretz M; Hébrard S; Leclerc J; Zarrinpashneh E; Soty M; Mithieux G; Sakamoto K; Andreelli F; Viollet B
J Clin Invest; 2010 Jul; 120(7):2355-69. PubMed ID: 20577053
[TBL] [Abstract][Full Text] [Related]
20. Metformin inhibits inflammatory signals in the gut by controlling AMPK and p38 MAP kinase activation.
Di Fusco D; Dinallo V; Monteleone I; Laudisi F; Marafini I; Franzè E; Di Grazia A; Dwairi R; Colantoni A; Ortenzi A; Stolfi C; Monteleone G
Clin Sci (Lond); 2018 Jun; 132(11):1155-1168. PubMed ID: 29540537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
